Dan Shelly

Chief Business Development Officer Immuthera / PolTREG

Seminars

Thursday 25th March 2027
Advancing CD6 CTLA-4 CAR-Treg Therapies Across T-Cell-Driven Autoimmune Diseases
8:30 am
  • Demonstrating clinical differentiation through targeting autoreactive T-cells rather than B-cells
  • Evaluating early clinical learnings across dermatological, neuroinflammatory, and metabolic autoimmune diseases
  • Leveraging insights from polyclonal and engineered Treg programs to guide future development strategies
Daniel Shelly